Paraparetic Guillain-Barré syndrome

Neurology

Volumn 82, Issue 22, 2014, Pages 1984-1989

  Van Den Berg, Bianca ^a   Fokke, Christiaan ^a,b   Drenthen, Judith ^a   Van Doorn, Pieter A ^a   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Gelre Hospitals Apeldoorn   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AREFLEXIA; ARM MUSCLE; ARM WEAKNESS; ARTICLE; CONTROLLED STUDY; CRANIAL NERVE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; HYPOREFLEXIA; INFECTION; LEG MUSCLE; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PARAPLEGIA; PRIORITY JOURNAL; QUADRIPLEGIA; SENSORY DYSFUNCTION; WALKING;

ADULT; AGED; DISABILITY EVALUATION; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; LEG; MALE; PARAPARESIS; PROSPECTIVE STUDIES; QUADRIPLEGIA;

EID: 84903955737     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000481     Document Type: Article

References (25)

1. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62: 1194-1198.
2. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7: 939-950.
3. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl): S21-S24.
4. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29: 599-612.
5. Mori M, Kuwabara S, Yuki N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev Neurother 2012;12: 39-51.
6. Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG; GBS-Consensus Group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001;45: 133-139.
7. Visser LH, Van der Meche FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain- Barré Study Group. Brain 1995;118: 841-847.
8. Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2014;85: 339-344.
9. Winer JB. Guillain-Barré syndrome: clinical variants and their pathogenesis. J Neuroimmunol 2011;231: 70-72.
10. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366: 2294-2304.
11. Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 2013;12: 1180-1188.
12. Ropper AH. Miller Fisher syndrome and other acute variants of Guillain-Barré syndrome. Baillieres Clin Neurol 1994;3: 95-106.
13. Carpo M, Pedotti R, Allaria S, et al. Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. J Neurol Sci 1999; 168: 78-84.
14. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326: 1130-1136.
15. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group. Ann Neurol 1994;35: 749-752.
16. Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 2010;74: 1680-1686.
17. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326: 1123-1129.
18. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363: 192-196.
19. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014;137: 33-43.
20. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2: 750-753.
21. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14: 1103-1109.
22. Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011; 76: 968-975.
23. Geleijns K, Roos A, Houwing-Duistermaat JJ, et al. Mannosebinding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol 2006;177: 4211-4217.
24. Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barré syndrome in preschool children. Neurology 2011;76: 807-810.
25. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology 1996;47: 813-817.